Projects & Cases
Official (Hunan MIIT): in 2024 Double-Crane invested 480 million yuan in an API base at Xiangzhong, which also obtained brexpiprazole registration and approval for sodium valproate sustained-release tablets.
Official (Hunan MIIT): in 2024 Double-Crane invested 480 million yuan in an API base at Xiangzhong, which also obtained brexpiprazole registration and approval for sodium valproate sustained-release tablets.